Indian Pharma Giants Bet on New Drug Launches to Drive Growth

India’s leading pharmaceutical companies are shifting their focus towards launching new medicines to boost revenue and reduce their dependence on existing products. Companies such as Dr. Reddy’s Laboratories, Sun Pharma, Cipla and Glenmark are exploring opportunities in high-demand segments, including diabetes and obesity treatments, respiratory medicines, cancer therapies and dermatology. Their plans, outlined during recent financial results discussions, indicate that new product launches are becoming a key part of their growth strategies. Dr. Reddy’s is preparing to expand the availability of semaglutide-based medicines in international markets. The company said it had resolved manufacturing-capacity issues and would resume supplies in November, subject to the completion of final quality checks. Cipla is targeting the launch of a peptide product in the US during the second half of the current financial year.

Respiratory medicines and specialised treatments are also emerging as important growth areas. Cipla, which has secured US approvals for generic versions of Ventolin and Advair, plans to introduce two more respiratory products in the second half of the financial year. Glenmark aims to launch generic Flovent 110 and ipratropium inhalers by the end of FY2026-27, strengthening its presence in the US market. Natco Pharma is exploring new cancer-treatment products for markets such as Brazil and Canada, while also working on semaglutide pen products for the US. Sun Pharma is looking to expand its dermatology portfolio through new treatment approvals. Meanwhile, companies are investing in manufacturing capacity to support future launches. Gland Pharma plans to invest ₹1,000 crore in setting up three injectable manufacturing lines at its Pashamylaram facility. Granules India is targeting the launch of five products in the US over the next two quarters. Regulatory approvals, production capacity and market competition will remain crucial to the success of these plans.